Development, validation and application of in-silico methods to predict the macromolecular targets of small organic compounds

Computational methods to predict the macromolecular targets of small organic drugs and drug-like compounds play a key role in early drug discovery and drug repurposing efforts. These methods are developed by building predictive models that aim to learn the relationships between compounds and their targets in order to predict the bioactivity of the compounds. In this thesis, we analyzed the strategies used to validate target prediction approaches and how current strategies leave crucial questions about performance unanswered. Namely, how does an approach perform on a compound of interest, with its structural specificities, as opposed to the average query compound in the test data? We constructed and present new guidelines on validation strategies to address these short-comings. We then present the development and validation of two ligand-based target prediction approaches: a similarity-based approach and a binary relevance random forest (machine learning) based approach, which have a wide coverage of the target space. Importantly, we applied a new validation protocol to benchmark the performance of these approaches. The approaches were tested under three scenarios: a standard testing scenario with external data, a standard time-split scenario, and a close-to-real-world test scenario. We disaggregated the performance based on the distance of the testing data to the reference knowledge base, giving a more nuanced view of the performance of the approaches. We showed that, surprisingly, the similarity-based approach generally performed better than the machine learning based approach under all testing scenarios, while also having a target coverage which was twice as large. After validating two target prediction approaches, we present our work on a large-scale application of computational target prediction to curate optimized compound libraries. While screening large collections of compounds against biological targets is key to identifying new bioactivities, it is resource intensive and challenging. Small to medium-sized libraries, that have been optimized to have a higher chance of producing a true hit on an arbitrary target of interest are therefore valuable. We curated libraries of readily purchasable compounds by: i. utilizing property filters to ensure that the compounds have key physicochemical properties and are not overly reactive, ii. applying a similaritybased target prediction method, with a wide target scope, to predict the bioactivities of compounds, and iii. employing a genetic algorithm to select compounds for the library to maximize the biological diversity in the predicted bioactivities. These enriched small to medium-sized compound libraries provide valuable tool compounds to support early drug development and target identification efforts, and have been made available to the community. The distinctive contributions of this thesis include the development and benchmarking of two ligand-based target prediction approaches under novel validation scenarios, and the application of target prediction to enrich screening libraries with biologically diverse bioactive compounds. We hope that the insights presented in this thesis will help push data driven drug discovery forward.Doktorgradsavhandlin

BonMOLière: Small-Sized Libraries of Readily Purchasable Compounds, Optimized to Produce Genuine Hits in Biological Screens across the Protein Space

Experimental screening of large sets of compounds against macromolecular targets is a key strategy to identify novel bioactivities. However, large-scale screening requires substantial experimental resources and is time-consuming and challenging. Therefore, small to medium-sized compound libraries with a high chance of producing genuine hits on an arbitrary protein of interest would be of great value to fields related to early drug discovery, in particular biochemical and cell research. Here, we present a computational approach that incorporates drug-likeness, predicted bioactivities, biological space coverage, and target novelty, to generate optimized compound libraries with maximized chances of producing genuine hits for a wide range of proteins. The computational approach evaluates drug-likeness with a set of established rules, predicts bioactivities with a validated, similarity-based approach, and optimizes the composition of small sets of compounds towards maximum target coverage and novelty. We found that, in comparison to the random selection of compounds for a library, our approach generates substantially improved compound sets. Quantified as the “fitness” of compound libraries, the calculated improvements ranged from +60% (for a library of 15,000 compounds) to +184% (for a library of 1000 compounds). The best of the optimized compound libraries prepared in this work are available for download as a dataset bundle (“BonMOLière”).publishedVersio

Development, validation and application of in-silico methods to predict the macromolecular targets of small organic compounds

Computational methods to predict the macromolecular targets of small organic drugs and drug-like compounds play a key role in early drug discovery and drug repurposing efforts. These methods are developed by building predictive models that aim to learn the relationships between compounds and their targets in order to predict the bioactivity of the compounds. In this thesis, we analyzed the strategies used to validate target prediction approaches and how current strategies leave crucial questions about performance unanswered. Namely, how does an approach perform on a compound of interest, with its structural specificities, as opposed to the average query compound in the test data? We constructed and present new guidelines on validation strategies to address these short-comings. We then present the development and validation of two ligand-based target prediction approaches: a similarity-based approach and a binary relevance random forest (machine learning) based approach, which have a wide coverage of the target space. Importantly, we applied a new validation protocol to benchmark the performance of these approaches. The approaches were tested under three scenarios: a standard testing scenario with external data, a standard time-split scenario, and a close-to-real-world test scenario. We disaggregated the performance based on the distance of the testing data to the reference knowledge base, giving a more nuanced view of the performance of the approaches. We showed that, surprisingly, the similarity-based approach generally performed better than the machine learning based approach under all testing scenarios, while also having a target coverage which was twice as large. After validating two target prediction approaches, we present our work on a large-scale application of computational target prediction to curate optimized compound libraries. While screening large collections of compounds against biological targets is key to identifying new bioactivities, it is resource intensive and challenging. Small to medium-sized libraries, that have been optimized to have a higher chance of producing a true hit on an arbitrary target of interest are therefore valuable. We curated libraries of readily purchasable compounds by: i. utilizing property filters to ensure that the compounds have key physicochemical properties and are not overly reactive, ii. applying a similaritybased target prediction method, with a wide target scope, to predict the bioactivities of compounds, and iii. employing a genetic algorithm to select compounds for the library to maximize the biological diversity in the predicted bioactivities. These enriched small to medium-sized compound libraries provide valuable tool compounds to support early drug development and target identification efforts, and have been made available to the community. The distinctive contributions of this thesis include the development and benchmarking of two ligand-based target prediction approaches under novel validation scenarios, and the application of target prediction to enrich screening libraries with biologically diverse bioactive compounds. We hope that the insights presented in this thesis will help push data driven drug discovery forward

BonMOLière: Small-Sized Libraries of Readily Purchasable Compounds, Optimized to Produce Genuine Hits in Biological Screens across the Protein Space

Experimental screening of large sets of compounds against macromolecular targets is a key strategy to identify novel bioactivities. However, large-scale screening requires substantial experimental resources and is time-consuming and challenging. Therefore, small to medium-sized compound libraries with a high chance of producing genuine hits on an arbitrary protein of interest would be of great value to fields related to early drug discovery, in particular biochemical and cell research. Here, we present a computational approach that incorporates drug-likeness, predicted bioactivities, biological space coverage, and target novelty, to generate optimized compound libraries with maximized chances of producing genuine hits for a wide range of proteins. The computational approach evaluates drug-likeness with a set of established rules, predicts bioactivities with a validated, similarity-based approach, and optimizes the composition of small sets of compounds towards maximum target coverage and novelty. We found that, in comparison to the random selection of compounds for a library, our approach generates substantially improved compound sets. Quantified as the “fitness” of compound libraries, the calculated improvements ranged from +60% (for a library of 15,000 compounds) to +184% (for a library of 1000 compounds). The best of the optimized compound libraries prepared in this work are available for download as a dataset bundle (“BonMOLière”)

Predicting the Skin Sensitization Potential of Small Molecules with Machine Learning Models Trained on Biologically Meaningful Descriptors

In recent years, a number of machine learning models for the prediction of the skin sensitization potential of small organic molecules have been reported and become available. These models generally perform well within their applicability domains but, as a result of the use of molecular fingerprints and other non-intuitive descriptors, the interpretability of the existing models is limited. The aim of this work is to develop a strategy to replace the non-intuitive features by predicted outcomes of bioassays. We show that such replacement is indeed possible and that as few as ten interpretable, predicted bioactivities are sufficient to reach competitive performance. On a holdout data set of 257 compounds, the best model (“Skin Doctor CP:Bio”) obtained an efficiency of 0.82 and an MCC of 0.52 (at the significance level of 0.20). Skin Doctor CP:Bio is available free of charge for academic research. The modeling strategies explored in this work are easily transferable and could be adopted for the development of more interpretable machine learning models for the prediction of the bioactivity and toxicity of small organic compounds